847148-20-3

Upstream product

• 871656-86-9 2-chloro-4-ethanesulphanyl-1-fluorobenzene 

Downstream Products

• 873194-15-1 2-chloro-4-(ethylsulfonyl)benzenethiol 
• 20945-58-8 2-chloro-4-(ethylsulfonyl)phenol 
• 934241-99-3 methyl {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-hydroxyphenyl}acetate 
• 942268-29-3 2-chloro-4-(ethylsulfonyl)-1-[(5-fluoro-2-methoxyphenyl)thio]benzene 
• 942268-49-7 5-{3-chloro-5-[2-chloro-4-(ethylsulfonyl)phenoxy]benzyl}-1H-tetrazole 
• 847149-14-8 2-{[2-chloro-4-(ethylsulfonyl)phenyl]amino}-4-fluorophenol 
• 847148-63-4 (4-chloro-2-{[2-chloro-4-(ethylsulfonyl)phenyl]amino}phenoxy)acetic acid 

Relevant academic research and scientific papers

NOVEL COMPOUNDS

The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES

The invention relates to substituted acids of formula (I), where T,W,X,Y,Z, R1 and R2 as defined in the claims, as useful pharmaceutical compounds for treating asthma and rhinitis, pharmaceutical compositions containing them, and a processes for their preparation.

HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

PHENOXIACETIC ACID DERIVATIVES

The invention relates to certain 2-substituted phenoxyacetic acid derivatives of formula (I), in which the variables are as defined in the claims, useful in the treatment of diseases or conditions in which modulation of the CRTh2 receptor is beneficial, s